how big is Guj. Terce Labs.?

As of Jun 06, Gujarat Terce Laboratories Ltd has a market capitalization of 42.00 Cr, classifying it as a Micro Cap company, with recent net sales of 32.25 Cr and a net profit of 1.59 Cr over the last four quarters.

Market Cap: As of Jun 06, Gujarat Terce Laboratories Ltd has a market capitalization of 42.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 32.25 Cr, and the sum of Net Profit for the same period is 1.59 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending Mar'24. Shareholder's Funds are reported at 7.11 Cr, and Total Assets amount to 22.05 Cr.

Who are in the management team of Guj. Terce Labs.?

As of March 2022, the management team of Guj. Terce Labs includes Amrutbhai P Prajapati (Whole-time Director), Aalap Prajapati (Managing Director & CEO), and Natwarbhai P Prajapati (Chairman & Whole-time Director), along with several Independent Directors: Chhayaben Ashwinbhai Shah, Viplav Suryakantbhai Khamar, Surendra Kumar Sharma, and Navinchandra Patel.

As of March 2022, the management team of Guj. Terce Labs includes the following individuals:<BR><BR>1. Amrutbhai P Prajapati - Whole-time Director<BR>2. Chhayaben Ashwinbhai Shah - Independent Director<BR>3. Viplav Suryakantbhai Khamar - Independent Director<BR>4. Aalap Prajapati - Managing Director & CEO<BR>5. Surendra Kumar Sharma - Independent Director<BR>6. Navinchandra Patel - Independent Director<BR>7. Natwarbhai P Prajapati - Chairman & Whole-time Director<BR><BR>These members play various roles within the company's governance and management structure.

When is the next results date for Guj. Terce Labs.?

No Upcoming Board Meetings

Has Guj. Terce Labs. declared dividend?

No Dividend History Available

Who are the peers of the Guj. Terce Labs.?

Guj. Terce Labs. peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Guj. Terce Labs. has below average management risk, growth, and capital structure, with a 1-year return of -2.13%.

Peers: The peers of Guj. Terce Labs. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, ANG Lifesciences, Shree Ganesh Bio, Concord Drugs, Veerhealth Care, and Vilin Bio Med.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs., while Below Average management risk is found at Guj. Terce Labs., ANG Lifesciences, Shree Ganesh Bio, Concord Drugs, Veerhealth Care, and Vilin Bio Med. Excellent growth is noted for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs., while Below Average growth is seen at Divi's Lab., Torrent Pharma, Guj. Terce Labs., ANG Lifesciences, Shree Ganesh Bio, Concord Drugs, Veerhealth Care, and Vilin Bio Med. Excellent capital structure is present in Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs., while Below Average capital structure is noted for Guj. Terce Labs., ANG Lifesciences, Shree Ganesh Bio, Concord Drugs, and Vilin Bio Med.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while ANG Lifesciences has the lowest at -44.35%. Guj. Terce Labs. has a 1-year return of -2.13%, which is higher than ANG Lifesciences but lower than Divi's Lab. Additionally, ANG Lifesciences, Shree Ganesh Bio, and Veerhealth Care all have negative six-month returns.

What is the technical trend for Guj. Terce Labs.?

As of May 6, 2025, Guj. Terce Labs has shifted to a bearish technical trend, indicated by a bearish MACD, moving averages, and KST, with the stock trading at 54.99 and showing a significant year-to-date decline compared to the Sensex.

As of 6 May 2025, the technical trend for Guj. Terce Labs has changed from mildly bearish to bearish. The current technical stance is bearish with a moderate strength. Key indicators driving this include a bearish MACD on the weekly chart, bearish moving averages on the daily chart, and a bearish KST on the weekly chart. Additionally, both the Bollinger Bands and Dow Theory indicate a mildly bearish trend on the weekly and monthly time frames. The stock is currently trading at 54.99, showing a significant decline year-to-date compared to the Sensex.

What does Guj. Terce Labs. do?

Gujarat Terce Laboratories Ltd is a Micro Cap company that produces branded generic pharmaceuticals for the domestic market. As of March 2025, it reported net sales of 123 Cr and a net loss of 34 Cr.

Overview: <BR>Gujarat Terce Laboratories Ltd produces branded generic formulations for the domestic market and operates within the Pharmaceuticals & Biotechnology industry, classified as a Micro Cap company.<BR><BR>History: <BR>Incorporated in 1985, Gujarat Terce Laboratories has developed a diverse product range over its more than three-decade journey. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 123 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: -34 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 39 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.44 <BR>Return on Equity: -11.06% <BR>Price to Book: 4.34<BR><BR>Contact Details: <BR>Address: 122/2 Ravi Estate, Bileshwarpura Chhatral Gandhinagar Gujarat : 382729 <BR>Tel: 91-079-6663 3706 <BR>Email: ho@gujaratterce.com <BR>Website: http://www.gujaratterce.com

Who are the top shareholders of the Guj. Terce Labs.?

The top shareholders of Guj. Terce Labs are Abundant Trade Link Private Limited with 14.5% and public shareholder Sagar Saxena with 1.39%. Individual investors hold a total of 59.34%, with no current institutional holdings.

The top shareholders of Guj. Terce Labs include Abundant Trade Link Private Limited, which holds the highest promoter stake at 14.5%. Additionally, the highest public shareholder is Sagar Saxena, with a holding of 1.39%. Overall, individual investors collectively hold a significant 59.34% of the company's shares. There are no institutional holdings from mutual funds or foreign institutional investors at this time.

Are Guj. Terce Labs. latest results good or bad?

Gujarat Terce Laboratories' latest Q2 FY26 results are concerning, showing flat year-on-year sales growth and a dramatic 71.88% decline in net profit, indicating significant operational challenges and poor profitability. Overall, the performance is characterized as bad, with a return on equity of only 2.69% and a one-year stock decline of 45.25%.

Gujarat Terce Laboratories' latest results for Q2 FY26 indicate a challenging situation for the company. While net sales showed a slight sequential growth of 1.91%, the year-on-year growth was essentially flat at 0.20%. More concerning is the dramatic decline in profitability, with net profit plummeting by 71.88% quarter-on-quarter to just ₹0.45 crores. <BR><BR>Operating profit margins also contracted sharply from 16.40% in the previous quarter to only 5.33%, signaling significant operational stress. This decline in margins is alarming, especially given the company's modest revenue growth and rising employee costs, which now account for 39% of sales.<BR><BR>Overall, the financial performance reflects serious operational challenges, with the company's return on equity at a mere 2.69% and a troubling recent ROE of -15.34%. The stock has also severely underperformed, with a one-year return of -45.25%, contrasting sharply with the broader market.<BR><BR>In summary, the results can be characterized as bad, highlighting significant issues in profitability, cost management, and overall operational efficiency.

Is Guj. Terce Labs. overvalued or undervalued?

As of November 17, 2025, Guj. Terce Labs. is considered very expensive and overvalued, with a PE ratio of -32.23 and poor stock performance, significantly lagging behind peers like Sun Pharma and Divi's Lab.

As of 17 November 2025, the valuation grade for Guj. Terce Labs. has moved from expensive to very expensive. This indicates a significant deterioration in its valuation outlook, suggesting that the company is overvalued. The key ratios highlight this concern, with a PE ratio of -32.23, a Price to Book Value of 4.39, and an EV to EBITDA of 7.59, all of which signal potential overvaluation when compared to industry norms.<BR><BR>In comparison to its peers, Guj. Terce Labs. stands out unfavorably; for instance, Sun Pharma has a PE ratio of 36.69 and an EV to EBITDA of 24.22, while Divi's Lab shows a PE of 69.78 and an EV to EBITDA of 52.44. These comparisons further reinforce the notion that Guj. Terce Labs. is not only overvalued but also lagging behind its competitors in terms of financial performance. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -47.76%, contrasting sharply with the Sensex's positive return of 8.72%.

Why is Guj. Terce Labs. falling/rising?

As of 03-Dec, Gujarat Terce Laboratories Ltd's stock price has risen to 44.58, reflecting a 1.3% increase, despite significant declines over the past year. The stock is currently outperforming its sector and seeing increased investor participation, although it remains below its moving averages, indicating potential long-term pressure.

As of 03-Dec, Gujarat Terce Laboratories Ltd is experiencing a rise in its stock price, currently at 44.58, reflecting an increase of 0.57 (1.3%). This upward movement is notable despite the stock's poor performance over longer periods, such as a year-to-date decline of 47.43% and a one-year drop of 41.30%, both compared to the Sensex which has shown positive returns.<BR><BR>Today's performance indicates that the stock has outperformed its sector by 1.31%, which may contribute to the positive sentiment surrounding it. Additionally, there has been a rise in investor participation, with a delivery volume of 6.22k on December 2, marking a 5.98% increase against the five-day average. This suggests that more investors are willing to buy and hold the stock, which can support a price increase.<BR><BR>However, it is important to note that Gujarat Terce Laboratories Ltd is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This indicates that while there is a short-term rise, the stock may still be under pressure in the longer term. Overall, the combination of today's outperformance and increased investor participation appears to be driving the current rise in the stock price.

Should I buy, sell or hold Guj. Terce Labs.?

How has been the historical performance of Guj. Terce Labs.?

Guj. Terce Labs has experienced a decline in net sales and profitability over the past three years, culminating in a loss of -2.52 Cr in the most recent fiscal year, with significant decreases in revenue and operating profit. The company's financial metrics indicate ongoing challenges in generating cash from core operations.

Answer:<BR>The historical performance of Guj. Terce Labs shows a decline in net sales and profitability over the past three years, culminating in a loss in the most recent fiscal year.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2021, Guj. Terce Labs reported net sales of 25.18 Cr, a significant decrease from 37.54 Cr in March 2020 and 31.03 Cr in March 2019. The total operating income mirrored this trend, remaining at 25.18 Cr in March 2021, down from 37.54 Cr in March 2020. The company's total expenditure, excluding depreciation, was 27.94 Cr in March 2021, which also saw a decline from 36.86 Cr in March 2020. This resulted in an operating profit (PBDIT) of -1.96 Cr in March 2021, a stark contrast to the positive figures of 0.97 Cr in March 2020 and 0.80 Cr in March 2019. Consequently, the profit before tax was -2.53 Cr in March 2021, compared to 0.44 Cr in March 2020 and 0.35 Cr in March 2019, leading to a profit after tax of -2.52 Cr in March 2021, down from 0.28 Cr in March 2020 and 0.43 Cr in March 2019. The earnings per share (EPS) reflected this downturn, falling to -3.4 in March 2021 from 0.38 in March 2020 and 0.58 in March 2019. The company's total liabilities decreased to 21.70 Cr in March 2021 from 22.34 Cr in March 2020, while total assets also declined to 21.70 Cr from 22.34 Cr in the same period. Cash flow from operating activities was stagnant at 0.00 Cr in March 2021, indicating challenges in generating cash from core operations. Overall, the financial metrics indicate a concerning trend for Guj. Terce Labs, with declining revenues and increasing losses.

Which are the latest news on Guj. Terce Labs.?